The Hope of a

Lifetime

We see a world where targeted therapies may alter the course of cancer for millions of patients.

Developing Cancer Treatments
with Precision Medicine

Aprea Therapeutics embraces the latest advancements in precision medicine and targeted cancer therapies. Our approach focuses on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects.

Specifically, we develop small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and intended to make treatments more effective at destroying cancer cells while sparing healthy tissue.

DNA Damage Response (DDR)
Targeted Therapeutics

Aprea believes that its unique approach may revolutionize the future of cancer treatment. Our small molecule therapeutics are being designed to maximize clinical activity while minimizing toxicity through increased selectivity.

A Robust Pipeline

Aprea’s robust pipeline explores multiple targets to improve our chances of success. We are committed to broadening the scope of our therapeutic portfolio to give patients renewed hope for beating cancer.

Advancing Novel Cancer Treatment

Every day we advance our clinical trials, we are one step closer to bringing DDR-targeted therapies to market. Our goal is to benefit the greatest number of cancer patients possible.